Company intelligence / Profile preview
Fulcrum Therapeutics
Cambridge, Massachusetts, United Statesfulcrumtx.com ↗
- Ownership
- Public · FULC
- Employees
- ~150
- Development stage
- Other
01
Overview
The lead program pociredir (FTX-6058) for sickle cell disease has completed enrollment in the Phase 1b PIONEER trial's 12 mg dose cohort with data expected early Q3 2025; the higher dose cohort enrollment started. Pociredir aims to increase fetal hemoglobin levels potentially transforming SCD treatment with an oral once-daily therapy. The FSHD program losmapimod was discontinued after a failed Phase 3 trial but data from this study are being shared openly with the FSHD research community[5][6][7].
- Therapeutic areas
- HematologyNeurology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Sanofi – collaboration and licensing agreement for losmapimod commercialization outside the U.S.[7]
04
Financials
- Market cap
- $280.8M
- Total revenue
- $0
- Enterprise value
- $-32.8M
Beyond the preview
Go deeper on Fulcrum Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fulcrum Therapeutics.